Solid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Rating of "Buy" by Analysts

Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) has earned a consensus recommendation of "Buy" from the eight brokerages that are presently covering the stock, MarketBeat reports. Six analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $15.67.

Several research firms recently issued reports on SLDB. JPMorgan Chase & Co. raised Solid Biosciences from a "neutral" rating to an "overweight" rating and upped their price target for the company from $10.00 to $15.00 in a research report on Monday, July 15th. Leerink Partners raised Solid Biosciences from a "market perform" rating to an "outperform" rating and set a $12.00 price target on the stock in a research report on Monday, June 24th. HC Wainwright reissued a "buy" rating and set a $16.00 price target on shares of Solid Biosciences in a research report on Wednesday, August 14th. William Blair raised Solid Biosciences to a "strong-buy" rating in a research report on Friday, August 30th. Finally, Leerink Partnrs raised Solid Biosciences from a "hold" rating to a "strong-buy" rating in a research report on Monday, June 24th.

Solid Biosciences Price Performance

NASDAQ SLDB traded up $0.06 on Monday, reaching $6.11. The company had a trading volume of 227,385 shares, compared to its average volume of 347,383. The firm has a market capitalization of $235.85 million, a PE ratio of -1.85 and a beta of 1.90. Solid Biosciences has a 1 year low of $1.81 and a 1 year high of $15.05. The firm has a 50-day moving average of $7.89 and a 200-day moving average of $8.44.

Solid Biosciences (NASDAQ:SLDB - Get Free Report) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.61) earnings per share for the quarter, topping analysts' consensus estimates of ($0.66) by $0.05. As a group, sell-side analysts expect that Solid Biosciences will post -2.61 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Point72 DIFC Ltd acquired a new position in shares of Solid Biosciences during the second quarter valued at $58,000. Cubist Systematic Strategies LLC acquired a new position in shares of Solid Biosciences during the second quarter valued at $412,000. Point72 Asset Management L.P. acquired a new position in shares of Solid Biosciences during the second quarter valued at $639,000. Algert Global LLC acquired a new position in shares of Solid Biosciences during the second quarter valued at $82,000. Finally, Susquehanna Fundamental Investments LLC acquired a new position in shares of Solid Biosciences during the second quarter valued at $92,000. 81.46% of the stock is owned by institutional investors and hedge funds.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.